查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球再生醫學市場：到 2028 年的預測——按產品、材料、應用、最終用戶和地區分析
市場調查報告書
商品編碼
1218897

全球再生醫學市場：到 2028 年的預測——按產品、材料、應用、最終用戶和地區分析

Regenerative Medicine Market Forecasts to 2028 - Global Analysis By Product, Material, Application, End User and Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC，全球再生醫學市場規模將在 2022 年達到 350.1 億美元，到 2028 年達到 739.4 億美元，預測期內復合年增長率為 13.27%。

再生醫學修復因疾病、外傷或先天性缺陷而受損的組織和器官，這與目前側重於治療症狀的臨床策略不同。 再生醫學包括組織工程、細胞療法、醫療器械、人造器官等，是實現這些突破的方法。 再生醫學是一個令人興奮的領域，旨在修復受損的組織和器官並恢復其功能。 它還旨在尋找治療永久性受損器官的方法。 這種方法旨在找到治愈以前無法治癒的疾病和傷害的方法。

根據再生醫學聯盟 (ARM) 2021 年報告，該市場的全球融資將從 2020 年的 199 億美元增加到 2021 年的 227 億美元，支持 2,406 種在研產品的增加。

市場動態

驅動程序

增加對研發活動的投資，從而推出創新產品

該行業不斷增加的投資導致了嚴肅的研發業務，各種投資者支持專注於開發市場上的新型療法和產品的初創企業。 它還為大規模合併、研究合作和夥伴關係鋪平了道路，以從研發活動中獲益。 除了商業公司，許多政府和政府資助的研究機構都在該行業致力於開發針對多種慢性疾病的有效治療方法，包括癌症、帕金森病、糖尿病、腎臟疾病和心血管疾病。正在積極投資於

抑製劑

高昂的治療費用和不完善的保險報銷政策

這些產品的高昂治療費用和不充分的報銷規定是市場擴張的主要障礙。 由於沒有大型保險公司的保險範圍，患者別無選擇，只能自費或通過眾籌支付治療費用，這會延誤治療並阻礙市場增長。 此外，對於患有各種遺傳疾病的廣大患者群體而言，批准的治療方法數量有限，這些方法相當昂貴並且可能有其他副作用，這限制了它們的採用並促進了市場的增長。正在阻止

機會

主要公司的戰略收購

全球再生醫學市場的趨勢是，主要競爭對手都在進行戰略收購以擴大其研發能力。 這個市場上的產品是從活細胞、蛋白質、□、抗體、抗體-藥物偶聯物 (ADC)、基因和細胞成分開發的各種專有技術，用於為各種慢性疾病創造救命藥物。 然而，將這些技術應用於臨床時，願望與現實之間可能存在不匹配。 一些領先的公司正專注於收購以提高其研發能力，以填補這一空白並推進針對不同臨床應用的研究。

威脅

缺乏熟練的專業人員

隨著再生醫學的進步，必要的技能有望得到發展。 再生醫學生物製造的快速擴張造成了該領域所需技能與市場容量之間的不匹配。 儘管對細胞和基因治療 (CGT) 業務進行了大量投資，但由於缺乏合格人員，製造這些藥物已被證明具有挑戰性。 勞動力有限和對新藥生產的了解不足導致 CGT 的商業化進程緩慢。

COVID-19 的影響

COVID-19 大流行為運營商提供了一個有利可圖的機會，因為迫切需要發現針對 SARS-COV-2 的新藥。 細胞和基因治療製造業正在進行多個項目，包括 T 細胞治療領域。 例如，新加坡杜克-新加坡國立大學醫學院的新發傳染病研究項目已經證明了這些免疫療法在治療感染 COVID-19 的患者中的有效性，這是基於先前的研究。 政府和公司為支持研發而採取的許多舉措和持續資助也加速了該行業的發展。 同樣，市場參與者為再生醫學研發籌集資金的舉措也在支持市場進步。

組織工程領域預計在預測期內將成為最大的領域

由於傷口護理中對支架、生物基質等產品的需求增加，組織工程領域預計將實現利潤豐厚的增長。 組織工程領域的高份額主要是由於能夠用完全活的結構替換受損結構的能力以及為以前無法治療的醫學問題找到治療方法的希望。 此外，為創造有效療法而進行的大量研發投資以及不斷推出成功的新產品預計將推動對組織工程行業的需求。

預計腫瘤科在預測期內的複合年增長率最高

由於全球癌症發病率高以及對開發癌症治療新技術的需求不斷增長，預計腫瘤學在預測期內將以最快的複合年增長率增長。 癌症患病率不斷上升等因素導致癌症患者群體的巨大需求未得到滿足，許多新藥（如 CAR-T 細胞療法）應運而生以滿足這一需求。 此外，通過研究資助和宣傳活動增加政府支持正在推動該領域的發展。

市場份額最高的地區

由於美國有眾多主要參與者，北美預計在預測期內將佔據最大的市場份額。 該地區擁有參與創新療法開發的先進技術和研究機構，臨床試驗的數量可能會有所貢獻。 與政府機構和私營公司的許多舉措一樣，財務靈活性是美國最大的收入來源。

複合年增長率最高的地區

隨著亞太地區新興國家擴大基礎設施和設施以促進乾細胞研究，預計在預測期內復合年增長率最高。 在日本，厚生勞動省於2013年4月通過了《再生醫學法》，為再生醫學和細胞療法的臨床發展鋪平了道路。 同樣，中國政府已經批准了各種關於人類胚胎幹細胞的研究項目，鼓勵研究人員探索這些細胞的臨床潛力。

主要發展

2021年1月，Integra Life Sciences Holdings Co., Ltd.完成對ACell, Inc.的收購。 收購 ACell 及其專有的 MatriStem UBM 技術將使 Integra 能夠為患者提供更全面的綜合傷口管理解決方案。

2021 年 1 月，Eli Lilly收購了 Prevail Therapeutics，旨在利用 Prevail 基於腺相關病毒 (AAV) 9 的基因療法治療神經退行性疾□□病患者，從而擴大與建立基因療法的協議程序。 此次收購擴大了以新方法解決神經退行性疾□□病的致命遺傳形式的努力。 此次收購增加了重要的技術和一支技術精湛的團隊，以補充Eli Lilly現有的專業知識。

2020 年 11 月，Novartis與 Mesoblast 達成協議，開發、商業化和製造用於治療急性呼吸窘迫綜合徵 (ARDS) 的 Remestemcel-L。 Remestemcel-L 可能是 ARDS 的第一個治療方法，它使用基於細胞的平台技術，即間充質基質細胞 (MSCs) 來治療這種致命疾病並改善預後。 在簽訂該許可協議後，Novartis計劃在與 COVID-19無關的 ARDS 中啟動 III 期試驗。

2020 年 10 月，Bayer AG收購了 Asklepios Biopharmaceutical，以拓寬其在細胞和基因治療領域的創新視野。 因此，Bayer AG的細胞和基因治療平台有可能為需求未得到滿足的多個疾病領域的患者帶來治療。

2018 年 10 月，Mesoblast Limited 擴大了與 JCR Pharmaceuticals Co., Ltd. 的合作夥伴關係。 在日本，一家日本公司開發了間充質乾細胞 (MSC)，用於治療新生兒缺氧缺血性腦病 (HIE)，這是一種大腦缺乏足夠血液供應和氧氣的疾病。與 JCR 擴大了合作關係。

本報告的內容

  • 區域和國家/地區細分市場份額評估
  • 針對新進入者的戰略建議
  • 2020、2021、2022、2025 和 2028 年的綜合市場數據
  • 涵蓋市場趨勢（市場驅動因素、驅動因素、機遇、威脅、挑戰、投資機會、建議）
  • 根據市場預測在關鍵業務領域提出戰略建議
  • 競爭格局映射主要共同趨勢
  • 公司簡介，包括詳細的戰略、財務狀況和近期發展
  • 映射最新技術進步的供應鏈趨勢

免費定制服務

訂閱此報告的客戶將免費獲得以下自定義選項之一。

  • 公司簡介
    • 其他市場參與者的綜合概況（最多 3 家公司）
    • 主要參與者的 SWOT 分析（最多 3 家公司）
  • 區域細分
    • 根據客戶要求對主要國家/地區的市場進行估算、預測和復合年增長率（注意：基於可行性檢查。）
  • 競爭基準
    • 根據產品組合、地域分佈和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 概覽
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究信息來源
    • 二手研究資源
    • 假設

第三章市場趨勢分析

  • 司機
  • 約束因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第 5 章全球再生醫學市場：按產品分類

  • 祖細胞和乾細胞療法
  • 基因治療
  • 人體組織工程
  • 細胞療法
  • 其他產品

第 6 章全球再生醫學市場：按材料分類

  • 轉基因材料
    • 轉基因
    • 基因工程細胞
    • 基因激活矩陣
    • 神經乾細胞
    • 三維聚合物技術
    • 成纖維細胞
  • 合成材料
    • 人工血管移植材料
    • 水凝膠材料
    • 腳手架
  • 生物材料
    • 異質材料
    • 膠原蛋白
  • 醫藥
    • 生物的

第 7 章全球再生醫學市場：按應用

  • 腫瘤科
  • 傷口護理
  • 心血管
  • 肌肉骨骼
  • 眼科
  • 其他應用

第 8 章全球再生醫學市場：按最終用戶分類

  • 政府和學術研究機構
  • 醫院和診所
  • 商業行業

第 9 章全球再生醫學市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東地區

第10章主要發展

  • 合同、夥伴關係、協作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • Smith & Nephew plc
  • Shenzhen SibionoGeneTech Co., Ltd.
  • AstraZeneca
  • Aspect Biosystems
  • Integra LifeSciences Corporation
  • Novartis AG
  • Medtronic plc
  • Amgen, Inc.
  • MiMedx Group
  • Baxter
  • Eli Lilly & Co.
  • Mesoblast Ltd.
  • Bayer AG
  • Corestem, Inc.
  • Bluebird Bio, Inc.
  • Regrow Biosciences Pvt. Ltd.Eli Lilly
Product Code: SMRC22433

According to Stratistics MRC, the Global Regenerative Medicine Market is accounted for $35.01 billion in 2022 and is expected to reach $73.94 billion by 2028 growing at a CAGR of 13.27% during the forecast period. Regenerative medicine repairs tissue or organs that have been damaged by disease, trauma, or congenital abnormalities, as opposed to the present clinical strategy, which focuses mostly on treating symptoms. The methods used to attain these breakthroughs include tissue engineering, cellular therapy, medical devices, and artificial organs. Regenerative medicine is an exciting field that aims to repair and restore the structure and function of damaged tissues and organs. It also intends to discover cures for permanently injured organs. This approach aims to find a cure for previously incurable illnesses and injuries.

According to the Alliance for Regenerative Medicine (ARM) 2021 report, the global financing in this market was raised to USD 22.7 billion in 2021 from USD 19.9 billion in 2020 to support 2,406 products that are under investigation.

Market Dynamics:

Driver:

Increasing investments in R&D activities leading to innovative product launches

Increasing investments in this sector have resulted in full-fledged research and development operations, as various investors support start-up firms focusing on the development of novel cures and products in the market. This has also paved the path for large mergers, research collaborations, and partnerships to profit from R&D operations. Aside from commercial businesses, numerous government and government-funded research organisations are aggressively investing in this industry to develop viable treatment options for a variety of chronic conditions such as cancer, Parkinson's disease, diabetes, renal disorders, cardiovascular diseases, and others.

Restraint:

High treatment costs and inadequate reimbursement policies

The high costs of therapy with these products, as well as a lack of reimbursement rules, are major obstacles limiting market expansion. Due to the lack of coverage provided by the major insurance providers, patients' only options are to pay for treatment out of pocket or through crowd fundraising, which delays treatment and inhibits market growth. Moreover, there are limited approved therapies for a wide range of patient population suffering from various genetic disorders which are considerably expensive and may have other side effects which restrains its adoption, limiting the market growth.

Opportunity:

Strategic acquisitions by key market players

One of the most prevalent worldwide regenerative medicine market trends is the incorporation of strategic acquisitions by key competitors in order to expand their R&D capabilities. This market's goods include a variety of unique techniques developed from living cells and protein, enzymes, antibodies, antibody-drug conjugates (ADC), gene and cellular components that have resulted in life-saving medicines for a variety of chronic diseases. However, there may be a mismatch between aspirations and realities when it comes to putting these technologies into clinical practise. Some significant businesses are focusing on acquisitions to boost their R&D capabilities in order to bridge this gap and develop research in diverse clinical applications.

Threat:

Shortage of skilled professionals

The skills necessary are projected to evolve as regenerative medicine progresses. Regenerative medicine bio manufacturing is rapidly expanding, resulting in a mismatch between the skill sets required by labourers in the workplace and the market's incapacity to fill those positions. Despite significant investment in the cell and gene therapies (CGT) business, producing these medicines has proven difficult due to a dearth of competent individuals. A limited workforce and inadequate understanding involved with manufacturing novel and emerging medicines contribute to the slow commercialization of CGTs.

COVID-19 Impact

The COVID-19 pandemic presented profitable chances for operational players due to the urgent need for the discovery of novel medicines against SARS-COV-2. Several projects are being conducted in the cell and gene therapy manufacturing industry, including the T-cell therapy space. For example, the Duke-NUS medical school's emerging infectious diseases research programme in Singapore demonstrated the usefulness of these immunotherapies in treating patients with COVID-19 infection based on earlier research findings. The availability of many initiatives and ongoing funding by government and corporate entities to assist R&D also accelerates the industry's advancement. Similarly, initiatives adopted by market players to raise finance for the R&D of regenerative medicine support the market progression.

The tissue-engineering segment is expected to be the largest during the forecast period

The tissue-engineering segment is estimated to have a lucrative growth, due to increased demand for its products, such as scaffolds, bio matrixes, and others in wound care. The primary reason for the large share of the tissue-engineering segment is the ability to replace a damaged structure with a totally living structure, as well as the promise for finding remedies for previously untreatable medical problems. Furthermore, significant investment in research & development for generating effective treatments, as well as the continuous introduction of new and successful products, are projected to drive demand in the tissue engineering industry.

The oncology segment is expected to have the highest CAGR during the forecast period

The oncology segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the high incidence of cancer globally and increasing demand for development of new technologies for the treatment of cancer. Factors such as the increased prevalence of cancer have resulted in huge unmet cancer patient population demands, and numerous novel medicines, such as CAR-T cell therapy, have been created to meet this demand. Furthermore, increased active government support through research grants and awareness campaigns is adding to the segment's growth.

Region with highest share:

North America is projected to hold the largest market share during the forecast period owing to the presence of a significant number of key players in the U.S. The presence of advanced technology and research institutes involved in the development of innovative treatments contribute to the high number of clinical trials in this region. The availability of finances, as well as many initiatives by government and private organisations, contributes to the largest revenue flow from the United States.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the expansion of infrastructure and facilities to accelerate stem cell research in the emerging economies of the region. In Japan, the Ministry of Health, Labor, and Welfare passed the Regenerative Medicine Law in April 2013, paving the way for the clinical development of regenerative and cell-based therapies. Similarly, the Chinese government has allowed various human embryonic stem cell research operations, encouraging researchers to investigate the clinical potential of these cells.

Key players in the market

Some of the key players profiled in the Regenerative Medicine Market include Smith & Nephew plc, Shenzhen SibionoGeneTech Co., Ltd., AstraZeneca, Aspect Biosystems, Integra LifeSciences Corporation, Novartis AG, Medtronic plc, Amgen, Inc., MiMedx Group, Baxter, Eli Lilly & Co., Mesoblast Ltd., Bayer AG, Corestem, Inc., Bluebird Bio, Inc. and Regrow Biosciences Pvt. Ltd.

Key Developments:

In January 2021, Integra LifeSciences Holdings Corporation completed the acquisition of ACell, Inc. Acquiring ACell and its proprietary MatriStem UBM technologies enabled Integra to provide more comprehensive complex wound management solutions to address patients.

In January 2021, Eli Lilly & Co. acquired Prevail Therapeutics with a deal to establish a gene therapy program at pharma giant anchored by Prevail's Adeno-Associated Virus (AAV)9-based gene therapies for patients with neurodegenerative diseases. The deal broadened their commitment to address fatal genetic forms of neurodegenerative disease through new modalities. This acquisition bought critical technology and highly skilled teams to complement the existing expertise at Lilly.

In November 2020, Novartis collaborated with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of Acute Respiratory Distress Syndrome (ARDS). As a potential first ARDS therapy, remestemcel-L used Mesenchymal Stromal Cells (MSCs), a cell-based platform technology, to treat this deadly condition and improve outcomes. Novartis intended to initiate a Phase III study in non-COVID-19-related ARDS after the anticipated closing of this license agreement.

In October 2020, Bayer acquired Asklepios BioPharmaceutical to broaden the innovation base in cell and gene therapy. This fueled Bayer's cell and gene therapy platform with potential to bring treatments to patients across multiple disease areas with high unmet need.

In October 2018, Mesoblast Limited expanded its partnership with JCR Pharmaceuticals Co. Ltd. in Japan to the use of mesenchymal stem cells (MSCs) for the treatment of new-borns who lack sufficient blood supply and oxygen to the brain, a condition termed neonatal hypoxic ischemic encephalopathy (HIE).

Products Covered:

  • Progenitor and Stem Cell Therapies
  • Gene Therapies
  • Tissue-Engineering
  • Cell Therapies
  • Other Products

Materials Covered:

  • Genetically Engineered Material
  • Synthetic material
  • Biologically derived material
  • Pharmaceutical

Applications Covered:

  • Oncology
  • Wound Care
  • Cardiovascular
  • Musculoskeletal
  • Ophthalmology
  • Other Applications

End Users Covered:

  • Government & Academic Research Institutes
  • Hospitals & Clinics
  • Commercial Industries

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Regenerative Medicine Market, By Product

  • 5.1 Introduction
  • 5.2 Progenitor and Stem Cell Therapies
  • 5.3 Gene Therapies
  • 5.4 Tissue-Engineering
  • 5.5 Cell Therapies
  • 5.6 Other Products

6 Global Regenerative Medicine Market, By Material

  • 6.1 Introduction
  • 6.2 Genetically Engineered Material
    • 6.2.1 Transgenics
    • 6.2.2 Genetically Manipulated Cell
    • 6.2.3 Gene-Activated Matrices
    • 6.2.4 Neural Stem Cell
    • 6.2.5 Three-Dimensional Polymer Technology
    • 6.2.6 Fibroblast
  • 6.3 Synthetic material
    • 6.3.1 Artificial vascular graft material
    • 6.3.2 Hydrogel material
    • 6.3.3 Scaffold
  • 6.4 Biologically derived material
    • 6.4.1 Xenogeneic material
    • 6.4.2 Collagen
  • 6.5 Pharmaceutical
    • 6.5.1 Biologic

7 Global Regenerative Medicine Market, By Application

  • 7.1 Introduction
  • 7.2 Oncology
  • 7.3 Wound Care
  • 7.4 Cardiovascular
  • 7.5 Musculoskeletal
  • 7.6 Ophthalmology
  • 7.7 Other Applications

8 Global Regenerative Medicine Market, By End User

  • 8.1 Introduction
  • 8.2 Government & Academic Research Institutes
  • 8.3 Hospitals & Clinics
  • 8.4 Commercial Industries

9 Global Regenerative Medicine Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Smith & Nephew plc
  • 11.2 Shenzhen SibionoGeneTech Co., Ltd.
  • 11.3 AstraZeneca
  • 11.4 Aspect Biosystems
  • 11.5 Integra LifeSciences Corporation
  • 11.6 Novartis AG
  • 11.7 Medtronic plc
  • 11.8 Amgen, Inc.
  • 11.9 MiMedx Group
  • 11.10 Baxter
  • 11.11 Eli Lilly & Co.
  • 11.12 Mesoblast Ltd.
  • 11.13 Bayer AG
  • 11.14 Corestem, Inc.
  • 11.15 Bluebird Bio, Inc.
  • 11.16 Regrow Biosciences Pvt. Ltd.

List of Tables

  • 1 Global Regenerative Medicine Market Outlook, By Region (2020-2028) ($MN)
  • 2 Global Regenerative Medicine Market Outlook, By Product (2020-2028) ($MN)
  • 3 Global Regenerative Medicine Market Outlook, By Progenitor and Stem Cell Therapies (2020-2028) ($MN)
  • 4 Global Regenerative Medicine Market Outlook, By Gene Therapies (2020-2028) ($MN)
  • 5 Global Regenerative Medicine Market Outlook, By Tissue-Engineering (2020-2028) ($MN)
  • 6 Global Regenerative Medicine Market Outlook, By Cell Therapies (2020-2028) ($MN)
  • 7 Global Regenerative Medicine Market Outlook, By Other Products (2020-2028) ($MN)
  • 8 Global Regenerative Medicine Market Outlook, By Material (2020-2028) ($MN)
  • 9 Global Regenerative Medicine Market Outlook, By Genetically Engineered Material (2020-2028) ($MN)
  • 10 Global Regenerative Medicine Market Outlook, By Transgenics (2020-2028) ($MN)
  • 11 Global Regenerative Medicine Market Outlook, By Genetically Manipulated Cell (2020-2028) ($MN)
  • 12 Global Regenerative Medicine Market Outlook, By Gene-Activated Matrices (2020-2028) ($MN)
  • 13 Global Regenerative Medicine Market Outlook, By Neural Stem Cell (2020-2028) ($MN)
  • 14 Global Regenerative Medicine Market Outlook, By Three-Dimensional Polymer Technology (2020-2028) ($MN)
  • 15 Global Regenerative Medicine Market Outlook, By Fibroblast (2020-2028) ($MN)
  • 16 Global Regenerative Medicine Market Outlook, By Synthetic material (2020-2028) ($MN)
  • 17 Global Regenerative Medicine Market Outlook, By Artificial vascular graft material (2020-2028) ($MN)
  • 18 Global Regenerative Medicine Market Outlook, By Hydrogel material (2020-2028) ($MN)
  • 19 Global Regenerative Medicine Market Outlook, By Scaffold (2020-2028) ($MN)
  • 20 Global Regenerative Medicine Market Outlook, By Biologically derived material (2020-2028) ($MN)
  • 21 Global Regenerative Medicine Market Outlook, By Xenogeneic material (2020-2028) ($MN)
  • 22 Global Regenerative Medicine Market Outlook, By Collagen (2020-2028) ($MN)
  • 23 Global Regenerative Medicine Market Outlook, By Pharmaceutical (2020-2028) ($MN)
  • 24 Global Regenerative Medicine Market Outlook, By Biologic (2020-2028) ($MN)
  • 25 Global Regenerative Medicine Market Outlook, By Application (2020-2028) ($MN)
  • 26 Global Regenerative Medicine Market Outlook, By Oncology (2020-2028) ($MN)
  • 27 Global Regenerative Medicine Market Outlook, By Wound Care (2020-2028) ($MN)
  • 28 Global Regenerative Medicine Market Outlook, By Cardiovascular (2020-2028) ($MN)
  • 29 Global Regenerative Medicine Market Outlook, By Musculoskeletal (2020-2028) ($MN)
  • 30 Global Regenerative Medicine Market Outlook, By Ophthalmology (2020-2028) ($MN)
  • 31 Global Regenerative Medicine Market Outlook, By Other Applications (2020-2028) ($MN)
  • 32 Global Regenerative Medicine Market Outlook, By End User (2020-2028) ($MN)
  • 33 Global Regenerative Medicine Market Outlook, By Government & Academic Research Institutes (2020-2028) ($MN)
  • 34 Global Regenerative Medicine Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
  • 35 Global Regenerative Medicine Market Outlook, By Commercial Industries (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.